Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management
others experience faster regain if behavior remains unchanged
While these observational data cannot definitively establish causality and may be subject to residual confounding despite sophisticated analytical approaches, the consistency of findings across multiple large, geographically diverse cohorts using different methodologies substantially strengthens confidence in the hepatoprotective benefits of GLP-1-based therapies
In addition, general disease symptoms including reduced appetite, anorexia and altered intestinal motility often accompanying intestinal inflammation, might be linked to GLP-1 signaling (2, 30, 31)
Christen said she advises GLP-1 users to choose foods with less than 10 grams of fat per serving because fat can worsen symptoms like nausea and acid reflux